In vitro characterization of a novel polymeric system for preparation of amorphous solid drug dispersions

AAPS Journal

Volumn 16, Issue 4, 2014, Pages 685-697

  Mahmoudi, Zahra N ^a   Upadhye, Sampada B ^a   Ferrizzi, David ^a   Rajabi Siahboomi, Ali R ^a  

^a Colorcon Incorporated ^*  (United States)

Author keywords

amorphous solid dispersions; fluid bed drug layering; hypromellose (hydroxypropyl methylcellulose, HPMC); polyvinyl acetate phthalate (PVAP); solubility enhancement; sugar spheres (Suglets)

Indexed keywords

GLIPIZIDE; HYDROXYPROPYLMETHYLCELLULOSE; PHOSPHATE BUFFERED SALINE; POLYMER; POLYVINYL ACETATE PHTHALATE; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; DRUG; HYDROXYPROPYLMETHYLCELLULOSE-LACTOSE MATRIX; LACTOSE; METHYLCELLULOSE; POLYVINYL DERIVATIVE; POLYVINYLACETATE PHTHALATE POLYMER;

ARTICLE; CONCENTRATION RESPONSE; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SOLUBILITY; EVAPORATION; GLASS TRANSITION TEMPERATURE; IN VITRO STUDY; PHASE SEPARATION; PROCESS DEVELOPMENT; X RAY DIFFRACTION; ANALOGS AND DERIVATIVES; CHEMISTRY; DRUG STABILITY; MEDICINAL CHEMISTRY; PROCEDURES; SOLUBILITY;

CHEMISTRY, PHARMACEUTICAL; DRUG COMPOUNDING; DRUG STABILITY; GLIPIZIDE; HYPOGLYCEMIC AGENTS; LACTOSE; METHYLCELLULOSE; PHARMACEUTICAL PREPARATIONS; POLYMERS; POLYVINYLS; SOLUBILITY;

EID: 84903577341     PISSN: None     EISSN: 15507416     Source Type: Journal    
DOI: 10.1208/s12248-014-9590-y     Document Type: Article

References (24)

1. Serajuddin A. Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. J Pharm Sci. 1999;88(10):1058-66.
2. Brouwers J, Brewster ME, Augustijns P. Supersaturating drug delivery systems: the answer to solubility-limited oral bioavailability. J Pharm Sci. 2009;98(8):2549-72.
3. Yamashita K, Nakate T, Okimoto K, Ohike A, Tokunaga Y, Ibuki R, et al. Establishment of new preparation method for solid dispersion formulation of tacrolimus. Int J Pharm. 2003;267(1-2):79-91. (Pubitemid 37352952)
4. Ho HO, Su HL, Tsai T, Sheu MT. The preparation and characterization of solid dispersions on pellets using a fluidized-bed system. Int J Pharm. 1996;139:223-9. (Pubitemid 26276286)
5. Sun N, Wei X, Wu B, Chen J, Lu Y, Wu W. Enhanced dissolution of silymarin/polyvinylpyrrolidone solid dispersion pellets prepared by a one-step fluid-bed coating technique. Powder Technol. 2008;182:72-80. (Pubitemid 351173199)
6. Puri V, Dantuluri AK, Bansal A. Barrier coated drug layered particles for enhanced performance of amorphous solid dispersion dosage form. J Pharm Sci. 2011;101(1):342- 53.
7. Gilis P, De Conde VFV, Vandecruys RPG. Beads having a core coated with an antifungal and a polymer. 1997. WO94/05263.
8. Leuner C, Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm. 2000;50(1):47-60. (Pubitemid 30326688)
9. Friesen DT, Shanker R, Crew M, Smithey DT, Curatolo WJ, Nightingale JA. Hydroxypropyl methylcellulose acetate succinate-based spray-dried dispersions: an overview. Mol Pharm. 2008;5(6):1003-19.
10. DiNunzio JC, Miller DA, Yang W, McGinity JW, Williams 3rd RO. Amorphous compositions using concentration enhancing polymers for improved bioavailability of itraconazole. Mol Pharm. 2008;5(6):968-80.
11. Gao P. Amorphous pharmaceutical solids: characterization, stabilization, and development of marketable formulations of poorly soluble drugs with improved oral absorption. Mol Pharm. 2008;5(6):903-4.
12. Chiang P, Ran Y, Chou K, Cui Y, Sambrone A, Chan C, et al. Evaluation of drug load and polymer by using a 96-well plate vacuum dry system for amorphous solid dispersion drug delivery. AAPS PharmSciTech. 2012;13(2):713-22.
13. Khougaz K, Clas SD. Crystallization inhibition in solid dispersions of MK-0591 and poly(vinylpyrrolidone) polymers. J Pharm Sci. 2000;89(10):1325-34.
14. Miller DA, DiNunzio JC, Yang W, McGinity JW, Williams 3rd RO. Enhanced in vivo absorption of itraconazole via stabilization of supersaturation following acidic to neutral pH transition. Drug Dev Ind Pharm. 2008;34(8):890-902.
15. Miller DA, DiNunzio JC, Yang W, McGinity JW, Williams 3rd RO. Targeted intestinal delivery of supersaturated itraconazole for improved oral absorption. Pharm Res. 2008;25(6):1450-9.
16. Konno H, Handa T, Alonzo DE, Taylor LS. Effect of polymer type on the dissolution profile of amorphous solid dispersions containing felodipine. Eur J Pharm Biopharm. 2008;70:493-9.
17. Kennedy M, Hu J, Gao P, Li L, Ali-Reynolds A, Chal B, et al. Enhanced bioavailability of a poorly soluble VR1 antagonist using an amorphous solid dispersion approach: a case study. Mol Pharm. 2008;5(6):981-93.
18. Taylor LS, Zografi G. Spectroscopic characterization of interactions between PVP and indomethacin in amorphous molecular dispersions. Pharm Res. 1997;14(12):1691-8. (Pubitemid 28062912)
19. Guidance for Industry: Dissolution testing of immediate release solid oral dosage forms. F.D.A. 1997: p. 17.
20. Guidance for Industry: Extended release oral dosage forms: development, evaluation, and application of in vitro/in vivo correlations. F.D.A. 1997; 27.
21. Murdande SB, Pikal MJ, Shanker RM, Bogner RH. Solubility advantage of amorphous pharmaceuticals: I. A thermodynamic analysis. J Pharm Sci. 2010;99(3):1254-64.
22. Konno H, Taylor LS. Influence of different polymers on the crystallization tendency of molecularly dispersed amorphous felodipine. J Pharm Sci. 2006;95(12):2692-705. (Pubitemid 46093176)
23. Konno H, Taylor LS. Ability of different polymers to inhibit the crystallization of amorphous felodipine in the presence of moisture. Pharm Res. 2008;25(4):969-78. (Pubitemid 351661822)
24. Ilevbare GA, Liu H, Edgar KJ, Taylor LS. Understanding polymer properties important for crystal growth inhibition: impact of chemically diverse polymers on solution crystal growth of ritonavir. Cryst Growth Des. 2012;12:3133-43.